Le Lézard
Classified in: Health

Steven K. Wilson MD, FACS, FRCS Named New Global Medical Director for Rigicon


Prof. Steven K. Wilson was named as the new global medical director for Rigicon, Inc. effective May 2022. Prof. Wilson has five decades of experience and expertise in prosthetic urology. It is expected as Rigicon's new global medical director, he will contribute to product enhancements, coordinate compliance/regulation, and supervise clinical research.

RONKONKOMA, N.Y., May 28, 2022 /PRNewswire-PRWeb/ -- Prof. Steven K. Wilson has five decades of experience and expertise in prosthetic urology as a physician, surgeon, author, filmmaker, editor, professor, inventor (w/ patents), researcher, and innovator of new penile implant surgical techniques.

Steven K. Wilson, MD, FACS, FRCS, was formerly Professor of Urology at the University of Arkansas. The Steven K. Wilson Chair of Prosthetic Urology was endowed at this University in 2007. Through 49 years of practice and over 11,000 implants, he has performed prosthesis surgery in 54 countries and has been a visiting professor at most American training programs and numerous foreign centers. He is an author of over 257 peer-reviewed publications as well as 19 textbook chapters, 32 surgical videos, and 6 prosthetic urology textbooks. He was the 2010 recipient of the St Paul's Medal of the British Association of Urologic Surgeons, which is given yearly to a single urologist outside of the United Kingdom that has contributed significantly to world urology. In 2013, the F. Brantley Scott Award of Excellence was designated to Wilson. In 2017, he received the inaugural "Living Legend Award" of the Society of Urologic Prosthetic Surgeons. Last year the Sexual Medicine Society of North America honored Wilson with its Lifetime Achievement Award in Sexual Medicine. Commencing in 2021, the "Wilson Cup" is presented yearly at the AUA to the outstanding prosthetic urologist.

Prof. Steven K. Wilson is most recognized for his innovation of new surgical techniques, which have helped make the complex implantation of penile implants and sphincters less invasive. Many of the timely enhancements to the penile prosthesis and special implantation instruments/retractors are the result of Wilson's inventions & clinical research. It is expected as Rigicon's global medical director, he will contribute to product enhancements, coordinate compliance/regulation, and supervise clinical research.

About Rigicon
Rigicon's vision is to be the trusted scientific partner in changing the practice of prosthetic urology.

Rigicon is exclusively focused on designing, manufacturing, and marketing innovative prosthetic solutions that increase patient satisfaction. Our mission is to offer a unique and comprehensive portfolio of products and services and deliver high-quality, innovative prosthetic urology solutions accessible to all customers.

You can find out more at http://www.rigicon.com.

Media Contact

Mel Luleci, Rigicon, Inc., 1 8882029790, [email protected]

 

SOURCE Rigicon, Inc.


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: